Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives $48.00 Average Price Target from Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $48.00.

A number of research analysts have recently commented on COAG shares. Evercore started coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. Jefferies Financial Group boosted their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. HC Wainwright upped their price target on Hemab Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wedbush reiterated an “outperform” rating and issued a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday, July 13th. Finally, The Goldman Sachs Group assumed coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective on the stock.

Insiders Place Their Bets

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the stock in a transaction on Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This represents a 0.96% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have acquired a total of 2,970,541 shares of company stock worth $55,459,603 in the last 90 days.

Hemab Therapeutics Price Performance

Shares of COAG stock opened at $49.39 on Friday. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $52.15. The business’s fifty day moving average is $30.70. The company has a market capitalization of $2.31 billion and a price-to-earnings ratio of -2.06.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.